speb/financial-data huggingface dataset:
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 576100000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Pretax Income: 1563600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 784700000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
ASTRAZEN.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 619800000.00
ASTRAZEN.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -17500000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 105300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 105300000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 10005800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2596100000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 399900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 176900000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 15300000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 15300000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 5600000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 5600000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Restructuring And Mergern Acquisition: 967900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 56800000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 6327200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 6327200000.00
ASTRAZEN.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 7100000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 939000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 220200000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 1448400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Selling General And Administration: 220200000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Share Issued: 25000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 25000000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Special Income Charges: -883200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: -56800000.00
ASTRAZEN.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 51400000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 7703500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 7703500000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 7696900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 7696900000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: -229442210.28
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -14636115.71
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Tax Provision: 406200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 202200000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.26
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.26
ASTRAZEN.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -641900000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Assets: 15181200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 15181200000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 7703500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 7703500000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Debt: 357300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 357300000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 7703500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 7703500000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Total Expenses: 14984800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 4118000000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 7477700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 7477700000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 1757700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 1757700000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 447700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 447700000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 106400000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 106400000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Total Unusual Items: -883200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: -56800000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -883200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -56800000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Work In Process: 67700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 67700000.00
ASTRAZEN.NS balance_sheet (annual, 2025-03-31) — Working Capital: 6393500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 6393500000.00
ASTRAZEN.NS income_statement (annual, 2025-03-31) — Write Off: 4600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 1663600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 5263100000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 25002239.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 22.33
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 2954100000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 165700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 165700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 25002239.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 22.33
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 558300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — EBIT: 754200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — EBITDA: 919900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 2309000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 7200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 7200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Income: 558300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 558300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 558300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 558300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 558300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 558300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -7200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -7200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 923500000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 560990602.41
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Operating Income: 645400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 5263100000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 112400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 633200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 747000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 2954100000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 165700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 220200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Selling General And Administration: 220200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: -3600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -909397.59
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 188700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.25
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 4617700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: -3600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -3600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 1619900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 5590900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 5508900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 2202300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 77400000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 74800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 24997695.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 21.69
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 347900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 50000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 3993900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 4099500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 50000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 7990000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 3244900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 14555400000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 69100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 69100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 7774400000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 1023200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 25700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 25700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 24997695.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 21.69
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 542200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — EBIT: 734900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — EBITDA: 760600000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 397900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 2346000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 6700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 6700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 7786200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 7990000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 74800000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 278800000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 278800000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 27500000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Income: 542200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 542200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 542200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 542200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 542200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 542200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -6700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -6700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 397900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 7990000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 451000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 813500000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 581588052.73
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Operating Income: 726100000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 5590900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 25000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 388100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 755500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 7940000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 15700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 75000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 61700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 709600000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 397700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 1900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 105600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Payables: 5641100000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 728200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 3244900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 25700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 280100000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Selling General And Administration: 280100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 25000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: -52900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 7990000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 7990000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -13511947.27
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 186000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.26
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 16145700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 7990000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 347900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 7990000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 4864800000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 8155700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 1590300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 381300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 132200000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: -52900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -52900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 6781000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 2041900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 6115700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 24992331.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 13.04
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 3663900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 38400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 38400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 24992331.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 13.04
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 325900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — EBIT: 476000000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — EBITDA: 514400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 2451800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 10600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 10600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Income: 325900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 325900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 325900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 325900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 325900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 325900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -10600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -10600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 499600000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 315536183.93
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Operating Income: 409900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 6115700000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 51300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 707300000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: -14800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 465400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 3663900000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 38400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 358400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Selling General And Administration: 358400000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 14800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 4436183.93
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 139500000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.30
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 5705800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 14800000.00
ASTRAZEN.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 14800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — +Operating Expense: 5492500000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 1290500000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — +Total Revenue: 22725800000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 5786100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 7827000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 7827000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 2136800000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 2136800000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -672900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -672900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -399500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -399500000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Amortization: 6600000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 6600000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Assets Held For Sale Current: 77400000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 77400000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 40000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 40000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 25000000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 25002786.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Basic EPS: 75.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 17.95
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 5361400000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 1445000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 1445000000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -36100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 1106600000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 1106600000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 50000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 50000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 4477200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 4477200000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4477200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4477200000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -800000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 4477200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 4477200000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -4788300000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 209300000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 118100000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Change In Payable: 3264000000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -454000000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -2173800000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -884200000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Common Stock: 50000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 50000000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Common Stock Dividend Paid: -800000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 8727900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 8727900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 0.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 14886900000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 3942500000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Current Assets: 17399300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 17399300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 139100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 139100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 139100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 139100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 9818100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 9818100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 621800000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 621800000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Depreciation: 279200000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 285800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 285800000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 56000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 279200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 56000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 25000000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 25002786.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Diluted EPS: 75.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 17.95
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1875200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 448800000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 9000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 9000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — EBIT: 2566900000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — EBIT: 601800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — EBITDA: 2852700000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — EBITDA: 657800000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — End Cash Position: 4477200000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -919700000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 10273300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 10273300000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -187500000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -1600000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 551600000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 0.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 2536300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 2536300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 1847600000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 1847600000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Gross Profit: 7838900000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 1843600000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Interest Expense: 44900000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 20400000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 44900000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 20400000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Interest Income: 232000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 232000000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -44900000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 220300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Inventory: 10273300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 10273300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 8727900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 8727900000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: 186900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 40000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 40000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 967500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 967500000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 967500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 967500000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 158300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 158300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 402300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 402300000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -9800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Income: 1875200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Income: 448800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 1875200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 448800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 1875200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 448800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1875200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 448800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1875200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 448800000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 2522000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 1875200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 448800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Interest Income: 187100000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -20400000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 187100000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -20400000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Net PPE: 1174700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 1174700000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -33400000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 8727900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 8727900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Revenue: 219200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 219200000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 378000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 378000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 158300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 158300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 899000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 899000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 2880200000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 668600000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Normalized Income: 1895647264.08
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 457136842.11
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: -151400000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Operating Income: 2346400000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Operating Income: 553100000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Operating Revenue: 22725800000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 5786100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 25000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 25000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 338200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 338200000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 324500000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 324500000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 65100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 65100000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -187100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 15700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 15700000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 219200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 219200000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 16000000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 59500000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 785300000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 476200000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Payable: 219200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 219200000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Properties: 1174700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 1174700000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 78900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 78900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 96400000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 96400000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Other Special Charges: -36900000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Other Special Charges: 10800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Payables: 8109300000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Payables: 8109300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 346700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 346700000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Pretax Income: 2522000000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 581400000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 223400000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -36100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 0.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 14886900000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 3942500000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 285800000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 56000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 9500000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 9500000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 9000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 9000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Restructuring And Mergern Acquisition: 52500000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 7358000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 7358000000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 2700000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 1246500000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 301300000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 1798100000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Selling General And Administration: 301300000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Share Issued: 25000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 25000000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Special Income Charges: -27500000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -10800000.00
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 10900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 8727900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 8727900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 8727900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 8727900000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -7052735.92
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -2463157.89
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Tax Provision: 646800000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 132600000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.26
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.23
ASTRAZEN.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -833100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Assets: 19891000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 19891000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 8727900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 8727900000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Debt: 1106600000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 1106600000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 8727900000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 8727900000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Total Expenses: 20379400000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 5233000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 11163100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 11163100000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 2491700000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 2491700000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 1345000000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 1345000000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 54100000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 54100000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -27500000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -10800000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -27500000.00
ASTRAZEN.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -10800000.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Work In Process: 0.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 0.00
ASTRAZEN.NS balance_sheet (annual, 2026-03-31) — Working Capital: 7581200000.00
ASTRAZEN.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 7581200000.00
ASTRAZEN.NS income_statement (annual, 2026-03-31) — Write Off: 11900000.00
ASTS balance_sheet (annual, 2021-12-31) — Accounts Receivable: 2173000.00
ASTS cash_flow (annual, 2021-12-31) — Amortization Cash Flow: 224000.00
ASTS cash_flow (annual, 2021-12-31) — Amortization Of Intangibles: 224000.00
ASTS cash_flow (annual, 2021-12-31) — Change In Other Current Liabilities: -398000.00
ASTS cash_flow (annual, 2021-12-31) — Change In Payables And Accrued Expense: 2091000.00
ASTS cash_flow (annual, 2021-12-31) — Depreciation: 2689000.00
ASTS cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of Business: 0.00
ASTS balance_sheet (annual, 2021-12-31) — Goodwill: 3641000.00
ASTS balance_sheet (annual, 2021-12-31) — Goodwill And Other Intangible Assets: 3641000.00
ASTS balance_sheet (annual, 2021-12-31) — Inventory: 1412000.00
ASTS cash_flow (annual, 2021-12-31) — Net Business Purchase And Sale: 0.00
ASTS cash_flow (annual, 2021-12-31) — Net Intangibles Purchase And Sale: 0.00
ASTS cash_flow (annual, 2021-12-31) — Net Preferred Stock Issuance: 0.00
ASTS balance_sheet (annual, 2021-12-31) — Non Current Prepaid Assets: 0.00
ASTS balance_sheet (annual, 2021-12-31) — Other Intangible Assets: 242000.00
ASTS income_statement (annual, 2021-12-31) — Other Operating Expenses: 29599000.00
ASTS cash_flow (annual, 2021-12-31) — Preferred Stock Issuance: 0.00
ASTS cash_flow (annual, 2021-12-31) — Purchase Of Intangibles: 0.00
ASTS cash_flow (annual, 2021-12-31) — Sale Of Business: 0.00
ASTS balance_sheet (annual, 2021-12-31) — Taxes Receivable: 1580000.00
ASTS balance_sheet (annual, 2021-12-31) — Total Tax Payable: 180000.00
ASTS income_statement (annual, 2022-12-31) — +Operating Expense: 152875000.00
ASTS income_statement (annual, 2022-12-31) — +Total Revenue: 13825000.00
ASTS balance_sheet (annual, 2022-12-31) — Accounts Payable: 13929000.00
ASTS balance_sheet (annual, 2022-12-31) — Accounts Receivable: 0.00
ASTS balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -6979000.00
ASTS balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 235384000.00
ASTS income_statement (annual, 2022-12-31) — Basic Average Shares: 54437073.00
ASTS income_statement (annual, 2022-12-31) — Basic EPS: -0.58
ASTS cash_flow (annual, 2022-12-31) — Beginning Cash Position: 324537000.00
ASTS balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 10268000.00
ASTS cash_flow (annual, 2022-12-31) — Capital Expenditure: -57284000.00
ASTS balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 7768000.00
ASTS balance_sheet (annual, 2022-12-31) — Capital Stock: 20000.00
ASTS balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 238588000.00
ASTS balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 238588000.00
ASTS cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 102340000.00
ASTS cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -31352000.00
ASTS cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -156464000.00
ASTS cash_flow (annual, 2022-12-31) — Change In Inventory: -2461000.00
ASTS cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -680000.00
ASTS cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -13830000.00
ASTS cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 18438000.00
ASTS cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -24588000.00
ASTS cash_flow (annual, 2022-12-31) — Change In Receivables: 16445000.00
ASTS cash_flow (annual, 2022-12-31) — Change In Working Capital: -24434000.00